The JenaValve pericardial transcatheter aortic valve replacement system to treat aortic valve disease.
Thomas PoschnerPaul WernerAlfred KocherGuenther LauferFrancesco MusumeciMartin AndreasMarco RussoPublished in: Future cardiology (2021)
Transcatheter aortic valve replacement is a valuable alternative technique to surgery and the spectrum of therapy continues to evolve. The JenaValve Pericaridal transcatheter aortic valve replacement System allows prosthesis fixation in a native, noncalcified aortic annulus with a unique paper clip-like anchorage mechanism. The low rate of paravalvular leakage and permanent pacemaker implantation emphasizes the further widespread use of the JenaValve - despite the limited data available. In May 2021, a CE mark for the transfemoral implantation in both aortic regurgitation and aortic stenosis was granted. However, no data have been published so far. The ongoing ALIGN trials are expected to provide the pending long-term data.
Keyphrases
- transcatheter aortic valve replacement
- aortic valve
- aortic stenosis
- transcatheter aortic valve implantation
- aortic valve replacement
- electronic health record
- minimally invasive
- big data
- systematic review
- stem cells
- coronary artery disease
- randomized controlled trial
- heart failure
- left ventricular
- coronary artery bypass
- artificial intelligence
- bone marrow
- atrial fibrillation